Vascular Solutions' ThrombiGel foam:
This article was originally published in Clinica
Vascular Solutions has received US FDA 510(k) clearance to market a gelatin foam version of its D-Stat Dry haemostatic product. ThrombiGel contains a gelatin foam pad - replacing the gauze pad in D-Stat Dry - to provide a, premixed, sterile, gelatin/thrombin haemostat. Howard Root, the firm's CEO, claimed that ThrombiGel was the only premixed thrombin/gelatin pad available in the US and was configured in a manner to "improve both ease-of-use and cost compared to standard gelatin pads used with thrombin". ThrombiGel is scheduled to enter the market in May 2005.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.